<DOC>
	<DOCNO>NCT00564863</DOCNO>
	<brief_summary>This strain dose-finding study CS19-ETEC strain WS0115A administer start inoculum 5 x 108 colony form unit ( cfu ) 5 subject initial step establish human disease model . If 80 % attack rate ( AR ) predefined diarrheal disease achieve without high output diarrhea , inoculum give 5 - 10 subject confirmation AR . If 80 % AR achieve , AR severity disease evaluate determine dose increase . The sequence may conduct DS26-1 necessary . If WS0115A strain cause high output diarrhea , dose adjust dose characterization continue . An iterative process use select optimal strain dose step review approve medical monitor .</brief_summary>
	<brief_title>Dose-Finding Study CS19 Expressing ETEC Challenge Strains</brief_title>
	<detailed_description>This phase 1 , open-label , strain dose-finding study design establish human challenge modelfor CS19-ETEC cause &gt; 80 % attack rate without cause high output diarrhea . This study design identical CS17 challenge model recently complete . Two strain CS19-ETEC isolate human diarrheal case identify characterized . Each clinical isolate use generate cGMP MCB procedure establish create fresh inoculum administer orally sodium bicarbonate solution challenge . Refer Section 8 full detail isolation preparation strain . CS19-ETEC strain WS0115A ( toxin phenotype LT+ ST+ serotype O114 : H- ) lead strain administer orally initial cohort 5 subject . This strain isolated stool 12-month-old Egyptian girl suffer watery diarrhea identify surveillance study conduct Abees , Egypt 1993 1995 investigator Naval Medical Research Unit-3 ( NAMRU-3 ) , Cairo , Egypt . A negative microbiologic work-up copathogens ( bacterialenteropathogens , rotavirus , Giardia lamblia , Entamoeba histolytica , Cryptosporidium ) support isolated WS0115A strain pathogenic child . Since strain LT+ST+ toxin phenotype , prefer strain lead testing challenge model , since heterologous protection bovine milk IgG anti-CsbD LT+ST+ phenotype would offer robust test protection afford anti-colonization . The alternate strain , CS-19 ETEC strain DS26-1 ( toxin phenotype LT+ST- ; serotype O8 : H9 ) isolate 1990 U.S. Navy Forward Laboratory U.S. soldier diarrhea deployment Saudi Arabia Operation Desert Shield . A negative microbiologic work-up copathogens ( Salmonella typhi , Vibrio cholerae , Giardia lamblia Entamoeba histolytica ) support isolated DS26-1 strain pathogenic individual . Each clinical isolate use generate cGMP master cell bank procedure establish create fresh inoculum administer orally sodium bicarbonate solution challenge . Refer Section 8 full detail isolation preparation strain .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<criteria>1 . Male female 18 45 year age , inclusive . 2 . General good health , without significant medical illness , abnormal physical examination finding clinical laboratory abnormality determine principal investigator ( PI ) PI consultation medical monitor Sponsor . 3 . Demonstrate comprehension protocol procedure knowledge ETEC illness pass write examination ( pas grade â‰¥ 70 % ) 4 . Willing participate inform consent obtain . 5 . Available entire inpatient portion study outpatient study visit . 6 . Negative serum pregnancy test screening ( initial visit day 7 3 ) negative urine pregnancy test day admission inpatient phase female subject childbearing potential . Females childbearing potential must agree use efficacious hormonal barrier method birth control study . Alternatively , abstinence alone acceptable . Female subject unable bear child must provide support documentation ( e.g. , prior tubal ligation hysterectomy ) . 1 . Presence significant medical condition , ( e.g. , psychiatric condition gastrointestinal disease , peptic ulcer , symptom evidence active gastritis gastroesophageal reflux disease , inflammatory bowel disease , alcohol illicit drug abuse/dependency ) , laboratory abnormality opinion investigator precludes participation study . 2 . Immunosuppressive illness IgA deficiency ( normal limit ) 3 . Positive serology result HIV , HBsAg , HCV antibodies . 4 . Significant abnormality screen laboratory hematology , serum chemistry , urinalysis , determine PI PI consultation medical monitor Sponsor . 5 . Allergy fluoroquinolones , cotrimoxazole , ampicillin/penicillin ( exclude allergic two three ) . 6 . Fewer 3 stool per week 3 stool per day usual frequency ; loose liquid stool occasional basis . 7 . History diarrhea 2 week prior plan inpatient phase . 8 . Regular use laxatives agent increase gastric pH ( regular define least weekly ) . 9 . Use antibiotic 7 day bacterial dose proton pump inhibitor , H2 blocker , antacid within 48 hour dose . 10 . Travel country ETEC cholera infection endemic ( develop world ) within two year prior dose . 11 . History vaccination ingestion ETEC , cholera , LT toxin . 12 . Stool culture ( collect 1 week prior admission ) positive ETEC bacterial enteric pathogen ( Salmonella , Shigella Campylobacter ) . 13 . Use investigational product within 30 day precede receipt challenge inoculum , plan use active study period . 14 . Use medication know affect immune function ( e.g. , corticosteroid ) within 30 day precede receipt challenge inoculum plan use active study period . ( Topical intraarticular steroid exclude subject ) . MANAGEMENT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Diarrhea</keyword>
	<keyword>ETEC</keyword>
</DOC>